Evidence map›Paper›PMID 31496993›Full record

ReviewFrontiers in endocrinology2019

Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Rossella E Nappi, Ellis Martini, Laura Cucinella, Silvia Martella, Lara Tiranini, Alessandra Inzoli, Emanuela Brambilla, David Bosoni, Chiara Cassani, Barbara Gardella

4 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05122065 unknown statusnot on this mapstarted 2021, after this paper: background citation

Defining the Vaginal Microbiome and the Vaginal pH of Menopausal Women With and Without Genitourinary Syndrome and With and Without Hormone Replacement Therapy

TypeobservationalSponsorFemTec Health Inc.Ran2021 to 2022Enrolled432ConditionsMenopause, Hormone Replacement Therapy, Genitourinary Syndrome of Menopause
NCT05464654 nacompletednot on this mapstarted 2021, after this paper: background citation

VABIP Study (Vaginal Biorevitalization With Polydeoxyribonucleotides) for the Improvement of the Genitourinary Syndrome of Menopause

TypeinterventionalSponsorHospital Regional 1o de OctubreRan2021 to 2022Enrolled136ConditionsGenitourinary Syndrome of Menopause, Postmenopausal Disorder, Menopause, Vagina AtrophyArms3 g Polynucleotide vaginal suppositories, Conjugated estrogens cream 1g Tube
NCT06398236 nacompletednot on this mapstarted 2023, after this paper: background citation

Multicentre, Exploratory, Prospective, Open-labelled, Non-controlled Study to Evaluate the Effect of SE5-OH Tablets on Healthy Women With Menopausal Symptoms

TypeinterventionalSponsorNutrition & Sante IberiaRan2023 to 2024Enrolled170ConditionsMenopauseArmsSE5-OH tablets
NCT07306611 phase1 / phase2completednot on this mapstarted 2024, after this paper: background citation

Regenerative Treatment of Female Genital Atrophy

TypeinterventionalSponsorAndreiaAntunesRan2024 to 2025Enrolled30ConditionsVulvo Vaginal AtrophyArmsMesotherapy with Autologous Platelet-Rich Plasma (PRP) to vulvovaginal area, Mesotherapy with saline solution, Platelet-Poor Plasma Gel
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 161 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and Safety of COMedicina (Kaunas, Lithuania) · 2026
    Trial
  3. Trial
  4. Efficacy ofNutrients · 2024
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rossella E NappiResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Ellis MartiniResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Laura CucinellaResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Silvia MartellaResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Lara TiraniniResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Alessandra InzoliResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Emanuela BrambillaResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
David BosoniResearch Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, University of Pavia, Pavia, Italy.
Chiara CassaniObstetrics and Gynecology Unit, IRCCS San Matteo Foundation, University of Pavia, Pavia, Italy.
Barbara GardellaDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
University of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaginal health is an essential component of active and healthy aging in women at midlife and beyond. As a consequence of hormonal deprivation and senescence, the anatomy and function of urogenital tissues are significantly affected and vulvovaginal atrophy (VVA) may occur. In a high proportion of postmenopausal women, progressive and chronic VVA symptoms have a strong impact on sexual function and quality of life. The new definition of genitourinary syndrome of menopause (GSM) comprises genital symptoms (dryness, burning, itching, irritation, bleeding), sexual symptoms (dyspareunia and other sexual dysfunctions) and urinary symptoms (dysuria, frequency, urgency, recurrent urinary infections). Many variables (age, sexual activity and partnership status) influence the clinical impact VVA/GSM symptoms and attitudes of elderly women to consult for receiving effective treatments. Psychosocial factors play a critical role in sexual functioning, but the integrity of the urogenital system is as well important affecting many domains of postmenopausal women's health, including sexual function. Several international surveys have extensively documented the need to improve VVA/GSM management because of the strong impact on women's daily life and on couple's intimacy. Health care providers (HCPs) need to be proactive in the early recognition of VVA/GSM in order to preserve urogenital and sexual longevity, by using hormonal and non-hormonal strategies. The clinical diagnosis is based on genital examination to identify objective signs and on the use of subjective scales to rate most bothersome symptoms (MBS), especially vaginal dryness. Recent studies point to the importance of addressing VVA/GSM as a potential early marker of poor general health in analogy with vasomotor symptoms. Therefore, a standard of VVA/GSM care in elderly women is desirable to enhance physical, emotional and mental well-being.

Indexed as

agingdyspareuniafemale sexual dysfunction (FSD)genito-urinary syndrome of menopause (GSM)longevityquality of life (QoL)vaginal drynessvulvovaginal atrophy (VVA)

Identifiers

PMID31496993
PMCPMC6712495
OpenAlexW2965274941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.